Dr.Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC including analytical development and quality control. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA.
Patrick has been serving on CBA board for several terms since 2003. His roles include directors of membership, activity, and alliance. He successfully organized CBA education seminar "Dragon Parents Summit Talk", and has been working as a committee member for Ho Family Scholarship. Besides CBA board member's duty, Patrick also participated many other activities in the Bay Area. He helped organize a big literature seminar for Sichuan earthquake fundraising, led local student math team and science bowl teams, took judge and judge leader roles in Silicon Valley science fair, and served as CABS journal editor "Trends in Bio/Pharmaceutical Industry" for seven years. He is also an active writer with many readers.
Dr. Mark Chen, Vice President. Dr. Chen is an immunologist with expertise in antibody design for therapeutic use and new vaccine discovery for the treatment of human
cancers and infectious disease. He completed his Ph.D. in Immunology
from Texas A&M University and has a track record of successful
leadership roles in R&D, business development, and the marketing of
therapeutic antibodies. Dr. Chen has been an active contributing Chinese
BioScience Association board member since 2014. He has
enthusiastically served CBA in the capacities of Secretary (2014, 2015)
and Vice President (2016).
Dr. Huifang Li, ViceDr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS diseases such as epilepsy, drug addiction, and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations.
Dr. Katherine Wang, Treasurer. Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Dr. Vivian Fu, CBA Membership. Dr. Fu received her Master degree in Immunology from Xi’an Jiaotong University, and Ph.D from Department of Pathology and Cell Biology at the University of South Florida. After graduation, she joined Moffitt Cancer Center as a Postdoc and worked on drug discovery and drug development. In 2013, Dr. Fu joined Bio-Rad as a Data Scientist and built Bio-Rad business intelligence platform and helped R&D, marketing, and sales teams on Business Development strategy, New Product Development, OEM decision, and marketing campaign.
Dr. Wenyi Chen, Alliance. Dr. Chen has been serving on CBA board for several terms since 2015. He helped organizing CBA workshop and annual conference. Wenyi currently works as Field Application Scientist at Nexcelom Bioscience and provides technical consultation in image cytometry, which has been widely used in immuno-oncology, 3D tumorspheroids and drug screening. Before joining Nexcelom in 2016, Wenyi conducted his research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation from human embryonic stem cells (hESCs) and the efficacy of the cell therapy using cardiac cells derived from hESCs. He received his Ph.D. from the Ohio State University and his B.S. from National Taiwan University.
Dr. Thomas Wei, Public Relations, Dr. Wei is now a postdoctoral researcher in Stanford University School of Medicine. His research currently focuses on drug discovery and cardiovascular disease modeling using human induced pluripotent stem cells (iPSC). He is the inventor of several International patents on new small molecule drugs and had experiences of technology transfer. Dr. Wei was supported by Stanford SPARK Program and joined Biomedical-Innovation and Entrepreneurship training course in Australia, 2014. He is a licensed and registered pharmacist in Taiwan, who has solid backgrounds and professional experimental skills in pharmacy, pharmacology and new drug discovery. Dr. Wei has been a board member and volunteer of Chinese Bioscience Association (CBA) since the end of 2016.
Dr. Michelle Chen, Advisor. Dr. Chen is a biotech entrepreneur & executive with extensive experience and successful track record in corporate development, R&D and commercialization. Currently she is an executive director of business development at Merck. Prior to that she served as the head of corporate development of several biotech companies and helped them with fund raising, partnerships, product development strategy, press release and investor relationship.
Dr. Chen started her biotech career in R&D at Scios (now Johnson & Johnson) and later Abgenix (now Amgen) as a group leader. She then went on to gain marketing and business development experience at global companies such as Agilent, Roche Dx and Roche Pharma where she was responsible for global business development licensing, collaborations, M&A and external pharma partnerships in personalized medicine, Dx and drug development deals.
Dr. Chen obtained a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF. In addition she received bioinformatics training at Stanford University.
Dr. Lin Sun-Hoffman, Advisor. A founding partner in Liu, Zheng, Chen & Hoffman LLP, Dr. Lin Sun-Hoffman is a patent attorney with 20-year experience focused on innovative life sciences. Lin has deep knowledge in all aspects of patent practices, ranging from policy, patent preparation and prosecution, due diligence, opinion work, through licensing and technology transfer negotiation.
In addition to her patent work, Lin has extensive experience with Chinese regulatory authorities, i.e., the Chinese FDA and the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ), and broader expertise in US and Chinese government affairs, serving clients ranging from start-up to Fortune-100.
Lin’s diverse background has prepared her to tackle the toughest challenges facing innovative life sciences companies today, starting with her time as a patent examiner at the United States Patent and Trademark Office (USPTO). She left USPTO to serve as managing patent counsel at Celera Genomics before joining the Life Technologies Corporation (formerly Applied Biosystems, now ThermoFisher). She is a frequent speaker in China, the US, and Europe, including participation at the invitation of USPTO to speak at SIPO and WIPO Conferences.
Lin also has over ten years of biomedical research experience including several years as a postdoctoral research fellow with several publications at the National Cancer Institute (NCI) of National Institutes of Health (NIH) in Frederick and Bethesda, Maryland. Lin currently serves as vice chair of LES International University-Industry-Government subcommittee, Bay Area Chapter head for BayHelix, Secretary General of US-China Green Energy Council. Lin was President of the Chinese Bioscience Association in Silicon Valley in 2013, and President of the Chinese Biopharmaceutical Association (CBA) 2008-2009. Lin also served as Chief Advisor for Asia at the Grocery Manufacturers Association (GMA) during 2011-2015, and Chief Advisor for Asia at Biotechnology Industry Organization’s (BIO) during 2009-2011.
Lin is also active in community activities including serving on the PTA executive council board (2015-2017) of Palo Alto School District, and teaches underprivileged students in rural area Yunnan China every summer.
Lin obtained her J.D., from University of Maryland School of Law (Maryland, U.S.); Ph.D. in Biochemistry, Cell and Molecular Biology from the University of Nevada Reno (Nevada, U.S.); and B.S. in Biology, East China Normal University (Shanghai, China). She is admitted in Maryland and U.S. Patent and Trademark Office
Dr. Shian-Jiun (SJ) Shih. Advisor (CBA Founding President). Dr. Shih is a consultant serving pharmaceutical and biotechnology clients, with more than twenty years’ of industrial experience and specializing in assay development and biomarkers.
From 2009 to 2015 she worked at the Translational Medicine Research Centre, Merck Research Laboratories, Merck Sharp & Dohme, most recently as the Director and Site Lead of Molecular Biomarkers and Diagnostics. She lead 29 scientists with broad translational research skills, including immunoassays, nucleic acid-based assays and next generation sequencing, mass spectrometry, flow cytometry, cell-based assays, immunohistory chemistry, and bioinformatics. Her group was responsible for developing clinical biomarker assays to support early phase clinical trials, including those for Keytruda, as well as for collaborating with academic leaders in biomarker discovery, and for building primate disease models for target validation studies.
Prior to joining Merck, she was with Cell Genesys, a biotechnology company developing cell-based immunotherapy and oncolytic adenovirus-based gene therapy products from 2001 to 2008. As the Director of Assay Development there, her group developed quality control and clinical monitoring assays for phase 3 clinical trials, and conducted product characterization studies to answer inquires from FDA, and from regulatory authorities from other countries.
During her time at Bayer Pharmaceuticals (2000-2001), SJ successfully developed liquid parenteral formulations and explored several novel drug delivery routes for biological drugs. From 1994 to 2000 she worked at Aventis (currently Sanofi) in various capacities, including characterization and purification of therapeutic monoclonal antibodies, development of a cell isolation medical device for bone marrow transplantation, liquid formulation and enhanced cellular delivery for gene therapy products. She started her industrial career in 1993 at BioSource (currently Invitrogen) and produced antibody reagents for research and in vitro diagnostic use.
SJ received a BS degree in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison, and completed her post-doctoral training at the department of Molecular Pharmacology at Stanford University.
Dr. Patty H Kiang, Advisor. Dr. Kiang is a consultant in Bio/Pharmaceutical industry supporting CMC Combination Products development and Quality systems.